Can high-dose aflibercept satisfy unmet treatment needs in diabetic macular oedema?
- PMID: 38461837
- DOI: 10.1016/S0140-6736(23)02760-5
Can high-dose aflibercept satisfy unmet treatment needs in diabetic macular oedema?
Conflict of interest statement
P-HG has received travel expenses from Théa Pharma, AbbVie/Allergan, Bayer, and Novartis and fees for medical consulting from Novartis, Roche, AbbVie/Allergan, Horus Pharma, Zeiss Meditec, and Bayer. CC-G has received fees for medical consulting from AbbVie/Allergan, Bayer, Horus Pharma, Novartis, Roche, Alcon, and Théa Pharma.
Comment on
-
Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial.Lancet. 2024 Mar 23;403(10432):1153-1163. doi: 10.1016/S0140-6736(23)02577-1. Epub 2024 Mar 7. Lancet. 2024. PMID: 38461843 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical